Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kimmo Porkka

Showing results (71-80 of 142) with videos related to

Pageof 15
Sort By:
Scientific Reports|June 6, 2014
Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapiesBhagwan Yadav, Tea Pemovska, Agnieszka Szwajda, et al.
Blood|April 3, 2019
<i>ERCC6L2</i> defines a novel entity within inherited acute myeloid leukemiaSuvi P M Douglas, Pihla Siipola, Panu E Kovanen, et al.
Leukemia|November 10, 2020
Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targetsShady Adnan-Awad, Daehong Kim, Helena Hohtari, et al.
Blood|December 19, 2013
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitorsHagop M Kantarjian, Jorge E Cortes, Dong-Wook Kim, et al.
Cancer Immunology Research|January 12, 2017
Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor ModelsCan Hekim, Mette Ilander, Jun Yan, et al.
Blood|May 13, 2011
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNetSimona Soverini, Andreas Hochhaus, Franck E Nicolini, et al.
Haematologica|July 13, 2019
Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemiaHeikki Kuusanmäki, Aino-Maija Leppä, Petri Pölönen, et al.
Leukemia|August 13, 2020
RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responsesShady Adnan Awad, Olli Dufva, Aleksandr Ianevski, et al.
Blood|September 14, 2016
IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft modelsHelena Ågerstam, Nils Hansen, Sofia von Palffy, et al.
Oncotarget|June 9, 2016
Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signalingDiede Brunen, María José García-Barchino, Disha Malani, et al.
Pageof 15

Showing results (71-80 of 142) with videos related to

Sort By:
Pageof 15
Scientific Reports|June 6, 2014
Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapiesBhagwan Yadav, Tea Pemovska, Agnieszka Szwajda, et al.
Blood|April 3, 2019
<i>ERCC6L2</i> defines a novel entity within inherited acute myeloid leukemiaSuvi P M Douglas, Pihla Siipola, Panu E Kovanen, et al.
Leukemia|November 10, 2020
Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targetsShady Adnan-Awad, Daehong Kim, Helena Hohtari, et al.
Blood|December 19, 2013
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitorsHagop M Kantarjian, Jorge E Cortes, Dong-Wook Kim, et al.
Cancer Immunology Research|January 12, 2017
Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor ModelsCan Hekim, Mette Ilander, Jun Yan, et al.
Blood|May 13, 2011
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNetSimona Soverini, Andreas Hochhaus, Franck E Nicolini, et al.
Haematologica|July 13, 2019
Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemiaHeikki Kuusanmäki, Aino-Maija Leppä, Petri Pölönen, et al.
Leukemia|August 13, 2020
RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responsesShady Adnan Awad, Olli Dufva, Aleksandr Ianevski, et al.
Blood|September 14, 2016
IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft modelsHelena Ågerstam, Nils Hansen, Sofia von Palffy, et al.
Oncotarget|June 9, 2016
Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signalingDiede Brunen, María José García-Barchino, Disha Malani, et al.
Pageof 15